Nicolas Arnold
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nicolas Arnold has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Beat Roth
Department of Urology, Inselspital, University Hospital of Bern, Wilhelm-Fabry-Haus, 3010, Bern, Switzerland
5 shared publicationsNicola Giudici
Department of Urology, Inselspital, University Hospital of Bern, Wilhelm-Fabry-Haus, 3010, Bern, Switzerland
4 shared publicationsBernhard Kiss
Department of Urology, Inselspital, University Hospital of Bern, Wilhelm-Fabry-Haus, 3010, Bern, Switzerland
3 shared publications- Bernhard Kiss
Department of Urology, University Hospital of Bern, Bern, Switzerland
3 shared publications - George Niklaus Thalmann
Department of Urology, University of Bern, 3010 Bern, Switzerland
3 shared publications Ilaria Lucca
3 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by SAGE Publications in Bladder Cancer
- Vol. 12 (3)
Intra- and extravesical recurrence after epirubicin-based hyperthermic intravesical chemotherapy (HIVEC) in patients with NMIBC and BCG failure: A multicenter retrospective Observational Study
Background: Guidelines recommend intravesical Bacillus Calmette-Guérin (BCG) as adjuvant therapy for intermediate- and high-risk non-muscle-invasive bladder cancer after transurethral resection. In the event of BCG failure, hyperthermic intravesical chemotherapy (HIVEC) represents a treatment alternative to patients who are surgically inoperable, or decline radical cystectomy. Objective: The aim of this study was to evaluate oncological outcomes in patients receiving epirubicin-based HIVEC as a second-line therapeutic approach. Methods: Retrospective inclusion of patients from our prospectively maintained, multicenter HIVEC database, who underwent HIVEC due to recurrent or persistent high-grade NMIBC following adequate BCG therapy (BCG failure) between November 2016 and December 2024. Survival was evaluated using Kaplan–Meier analysis and log-rank testing. Associations between clinicopathological factors and oncological outcomes were assessed using Cox regression analysis. Results: Sixty-five patients were included. Median follow-up was 38 months (IQR 21–55). Twenty-four patients (36.9%) experienced intravesical recurrence with a median intravesical recurrence-free survival (RFS) of 24 months (IQR 9-45) and 1-/2-year intravesical RFS rates of 77.9% and 64.1%, respectively. Extravesical recurrence was observed in 21 patients (32.3%) with a median extravesical RFS of 22 months (IQR 7-43) and 1-/2-year extravesical RFS rates of 81.3% and 70.9%, respectively. Higher number of recurrences prior to HIVEC were significantly associated with extravesical recurrence in univariate (HR 2.23; 95% CI 1.23-3.87; p=0.019) and multivariate analysis (HR 1.31; 95% CI 1.03-1.67; p=0.027). Conclusions: Although limited by the relatively small sample size, Epirubicin-based HIVEC demonstrated promising oncological outcomes indicating its potential value as bladder-preserving treatment option after BCG failure. Prospective controlled studies are warranted to further assess the role of epirubicin-based HIVEC in this setting.
- 10 August 2026
- Published by SAGE Publications in Bladder Cancer
- Vol. 12 (3)
Open AccessIntra- and extravesical recurrence after epirubicin-based hyperthermic intravesical chemotherapy (HIVEC) in patients with NMIBC and BCG failure: A multicenter retrospective Observational Study
Background: Guidelines recommend intravesical Bacillus Calmette-Guérin (BCG) as adjuvant therapy for intermediate- and high-risk non-muscle-invasive bladder cancer after transurethral resection. In the event of BCG failure, hyperthermic intravesical chemotherapy (HIVEC) represents a treatment alternative to patients who are surgically inoperable, or decline radical cystectomy. Objective: The aim of this study was to evaluate oncological outcomes in patients receiving epirubicin-based HIVEC as a second-line therapeutic approach. Methods: Retrospective inclusion of patients from our prospectively maintained, multicenter HIVEC database, who underwent HIVEC due to recurrent or persistent high-grade NMIBC following adequate BCG therapy (BCG failure) between November 2016 and December 2024. Survival was evaluated using Kaplan–Meier analysis and log-rank testing. Associations between clinicopathological factors and oncological outcomes were assessed using Cox regression analysis. Results: Sixty-five patients were included. Median follow-up was 38 months (IQR 21–55). Twenty-four patients (36.9%) experienced intravesical recurrence with a median intravesical recurrence-free survival (RFS) of 24 months (IQR 9-45) and 1-/2-year intravesical RFS rates of 77.9% and 64.1%, respectively. Extravesical recurrence was observed in 21 patients (32.3%) with a median extravesical RFS of 22 months (IQR 7-43) and 1-/2-year extravesical RFS rates of 81.3% and 70.9%, respectively. Higher number of recurrences prior to HIVEC were significantly associated with extravesical recurrence in univariate (HR 2.23; 95% CI 1.23-3.87; p=0.019) and multivariate analysis (HR 1.31; 95% CI 1.03-1.67; p=0.027). Conclusions: Although limited by the relatively small sample size, Epirubicin-based HIVEC demonstrated promising oncological outcomes indicating its potential value as bladder-preserving treatment option after BCG failure. Prospective controlled studies are warranted to further assess the role of epirubicin-based HIVEC in this setting.
- Open Access
Changing Face of Radical Prostatectomy: A Nationwide Registry Study of Case-Mix, Surgical Evolution, and Outcomes
Background/Objectives: We aimed to evaluate temporal changes in patient selection, surgical practice, and postoperative outcomes of radical prostatectomy in Switzerland (2020–2025) using a national registry. Methods: Data from 7687 patients undergoing radical prostatectomy were extracted from a prospective national registry (January 2020–March 2025). Preoperative, operative, and postoperative variables were compared descriptively using the Mann–Whitney U test for continuous variables and the chi-square test for categorical variables. Temporal trends were assessed using locally estimated scatterplot smoothing. Multivariable logistic regression analyses were performed for positive surgical margins and PSA persistence. Results: Baseline patient characteristics remained stable over time. The use of MRI-targeted biopsy increased from 46% to 84% (p < 0.001). The proportion of low-risk diseases being treated decreased from 7.1% to 4.0% (p = 0.040). Minimally invasive surgery increased from 81% to 95% (p < 0.001); pelvic lymph node dissection declined from 83% to 63% (p < 0.001). Operative time (205 vs. 185 min, p = 0.002) and blood loss (300 vs. 200 mL, p < 0.001) decreased over time. Lymph node invasion decreased from 11% to 6.0% (p = 0.001), positive surgical margins from 27% to 22% (p = 0.044), and prostate-specific antigen persistence from 18.5% to 11.3% (p = 0.001). Severe postoperative complications decreased from 2.5% to 0.8% (p = 0.014). After multivariable adjustment, surgery performed in 2024 remained independently associated with lower rates of positive surgical margins (OR 0.73, 95% CI 0.57–0.93) and PSA persistence (OR 0.26, 95% CI 0.19–0.37) compared with 2020. Conclusions: Using the Swiss national registry, we demonstrate that radical prostatectomy has evolved toward more risk-adapted patient selection, near-universal minimally invasive surgery, and more selective pelvic lymph node dissection. Despite a shift away from low-risk disease, perioperative and early oncological outcomes improved, likely reflecting a combination of evolving diagnostic pathways, increasing surgical experience, and broader changes in perioperative management.
Open AccessChanging Face of Radical Prostatectomy: A Nationwide Registry Study of Case-Mix, Surgical Evolution, and Outcomes
Background/Objectives: We aimed to evaluate temporal changes in patient selection, surgical practice, and postoperative outcomes of radical prostatectomy in Switzerland (2020–2025) using a national registry. Methods: Data from 7687 patients undergoing radical prostatectomy were extracted from a prospective national registry (January 2020–March 2025). Preoperative, operative, and postoperative variables were compared descriptively using the Mann–Whitney U test for continuous variables and the chi-square test for categorical variables. Temporal trends were assessed using locally estimated scatterplot smoothing. Multivariable logistic regression analyses were performed for positive surgical margins and PSA persistence. Results: Baseline patient characteristics remained stable over time. The use of MRI-targeted biopsy increased from 46% to 84% (p < 0.001). The proportion of low-risk diseases being treated decreased from 7.1% to 4.0% (p = 0.040). Minimally invasive surgery increased from 81% to 95% (p < 0.001); pelvic lymph node dissection declined from 83% to 63% (p < 0.001). Operative time (205 vs. 185 min, p = 0.002) and blood loss (300 vs. 200 mL, p < 0.001) decreased over time. Lymph node invasion decreased from 11% to 6.0% (p = 0.001), positive surgical margins from 27% to 22% (p = 0.044), and prostate-specific antigen persistence from 18.5% to 11.3% (p = 0.001). Severe postoperative complications decreased from 2.5% to 0.8% (p = 0.014). After multivariable adjustment, surgery performed in 2024 remained independently associated with lower rates of positive surgical margins (OR 0.73, 95% CI 0.57–0.93) and PSA persistence (OR 0.26, 95% CI 0.19–0.37) compared with 2020. Conclusions: Using the Swiss national registry, we demonstrate that radical prostatectomy has evolved toward more risk-adapted patient selection, near-universal minimally invasive surgery, and more selective pelvic lymph node dissection. Despite a shift away from low-risk disease, perioperative and early oncological outcomes improved, likely reflecting a combination of evolving diagnostic pathways, increasing surgical experience, and broader changes in perioperative management.
- Open Access
- 9 May 2026
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (10) , 4169-4177
Impact of SGLT2 inhibitors on urinary tract infections in patients with diabetes mellitus and ileal urinary diversion: a retrospective cohort study
Purpose: The impact of sodium–glucose linked transporter-2 inhibitors (SGLT2i) on urinary tract infection (UTI) risk remains uncertain and may be dose-dependent. No prior studies have evaluated their effect in patients with urinary diversion after cystectomy. This study evaluated the association between SGLT2i use and UTI in patients with diabetes mellitus (DM) after cystectomy and ileal urinary diversion. Methods: We conducted a retrospective single-center cohort study including all patients with DM who underwent cystectomy with ileal urinary diversion between March 1996 and November 2023. Primary outcome was UTI occurrence, assessed by incidence rate and infection-free survival (IFS). Secondary outcomes included asymptomatic bacteriuria and glucosuria. UTI incidence rate was compared using Poisson regression. IFS was evaluated using Kaplan–Meier curves, log-rank test and Cox regression analysis. Results: Among 123 included patients with DM and ileal urinary diversion, 18 (14.6%) received SGLT2i therapy. Median follow-up was 35 months (IQR 12–83). Overall, 121 UTI were documented, 6 (5.0%) in patients with and 115 (95.0%) without SGLT2i treatment, corresponding to incidence rates of 0.206 vs. 0.210 UTI/patient/year ( p = 0.959). Median IFS was 9 months (IQR 3–31) in the SGLT2i and 17 months (IQR 5–74) in the non-SGLT2i group, with no significant difference ( p = 0.489). Conclusion: In this cohort, SGLT2i therapy was not associated with an increased risk of UTI in patients with DM and ileal urinary diversion after cystectomy. These findings suggest no evident signal for increased infection risk; however, prospective studies are warranted to confirm these observations.
- 9 May 2026
- Published by Springer Nature in International Urology and Nephrology
- Vol. 58 (10) , 4169-4177
Open AccessImpact of SGLT2 inhibitors on urinary tract infections in patients with diabetes mellitus and ileal urinary diversion: a retrospective cohort study
Purpose: The impact of sodium–glucose linked transporter-2 inhibitors (SGLT2i) on urinary tract infection (UTI) risk remains uncertain and may be dose-dependent. No prior studies have evaluated their effect in patients with urinary diversion after cystectomy. This study evaluated the association between SGLT2i use and UTI in patients with diabetes mellitus (DM) after cystectomy and ileal urinary diversion. Methods: We conducted a retrospective single-center cohort study including all patients with DM who underwent cystectomy with ileal urinary diversion between March 1996 and November 2023. Primary outcome was UTI occurrence, assessed by incidence rate and infection-free survival (IFS). Secondary outcomes included asymptomatic bacteriuria and glucosuria. UTI incidence rate was compared using Poisson regression. IFS was evaluated using Kaplan–Meier curves, log-rank test and Cox regression analysis. Results: Among 123 included patients with DM and ileal urinary diversion, 18 (14.6%) received SGLT2i therapy. Median follow-up was 35 months (IQR 12–83). Overall, 121 UTI were documented, 6 (5.0%) in patients with and 115 (95.0%) without SGLT2i treatment, corresponding to incidence rates of 0.206 vs. 0.210 UTI/patient/year ( p = 0.959). Median IFS was 9 months (IQR 3–31) in the SGLT2i and 17 months (IQR 5–74) in the non-SGLT2i group, with no significant difference ( p = 0.489). Conclusion: In this cohort, SGLT2i therapy was not associated with an increased risk of UTI in patients with DM and ileal urinary diversion after cystectomy. These findings suggest no evident signal for increased infection risk; however, prospective studies are warranted to confirm these observations.
- Open Access
- 5 May 2026
- Published by AccScience Publishing in Eurasian Journal of Medicine and Oncology
- Vol. 10 (3) , 025470485
Long-term oncologic outcomes of epirubicin-based hyperthermic intravesical chemotherapy in BCG-naive patients with non-muscle-invasive bladder cancer: A multicenter retrospective observational study
Introduction: Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of bladder cancer cases and demonstrates substantial variability in recurrence and progression. Bacillus Calmette–Guérin (BCG) is the recommended adjuvant intravesical therapy in intermediate- and high-risk tumors; however, shortages and contraindications necessitate alternative treatments. Hyperthermic intravesical chemotherapy (HIVEC) has been mainly studied with mitomycin C, and data on epirubicin-based HIVEC are limited. Objective: This study evaluated first-line epirubicin-based HIVEC in BCG-naive patients with NMIBC. Methods: In this study, we included and retrospectively analyzed BCG-naive patients from our prospectively recorded, multicenter HIVEC database who received HIVEC in a first-line setting between March 2017 and September 2022. Treatment included six weekly induction instillations followed by six monthly maintenance instillations. The primary outcome was recurrence-free survival (RFS), while secondary outcomes included progression-free survival, extravesical RFS, disease-free survival, cancer-specific survival, and the need for radical cystectomy. Results: Twenty-three patients with intermediate-, high-, or very high-risk NMIBC received epirubicin-based HIVEC in a first-line setting. The median follow-up was 35 months (IQR 29–52). Two patients (8.7%) experienced intravesical recurrence (both carcinoma in situ). Median RFS was 35 months (IQR 26–50), with 1- and 2-year RFS rates of 100.0% and 95.6%, respectively. No patient experienced progression, extravesical recurrence, cancer-specific death, or required radical cystectomy. Conclusion: First-line epirubicin-based HIVEC in BCG-naive patients provided durable oncological control in predominantly high- and very high-risk NMIBC. These results indicate that epirubicin-based HIVEC may represent a potential alternative when BCG is unavailable or contraindicated. However, the small sample size and observational design limit interpretability, underscoring the need for larger randomized trials to clarify the role of epirubicin-based HIVEC in this setting.
- 5 May 2026
- Published by AccScience Publishing in Eurasian Journal of Medicine and Oncology
- Vol. 10 (3) , 025470485
Open AccessLong-term oncologic outcomes of epirubicin-based hyperthermic intravesical chemotherapy in BCG-naive patients with non-muscle-invasive bladder cancer: A multicenter retrospective observational study
Introduction: Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of bladder cancer cases and demonstrates substantial variability in recurrence and progression. Bacillus Calmette–Guérin (BCG) is the recommended adjuvant intravesical therapy in intermediate- and high-risk tumors; however, shortages and contraindications necessitate alternative treatments. Hyperthermic intravesical chemotherapy (HIVEC) has been mainly studied with mitomycin C, and data on epirubicin-based HIVEC are limited. Objective: This study evaluated first-line epirubicin-based HIVEC in BCG-naive patients with NMIBC. Methods: In this study, we included and retrospectively analyzed BCG-naive patients from our prospectively recorded, multicenter HIVEC database who received HIVEC in a first-line setting between March 2017 and September 2022. Treatment included six weekly induction instillations followed by six monthly maintenance instillations. The primary outcome was recurrence-free survival (RFS), while secondary outcomes included progression-free survival, extravesical RFS, disease-free survival, cancer-specific survival, and the need for radical cystectomy. Results: Twenty-three patients with intermediate-, high-, or very high-risk NMIBC received epirubicin-based HIVEC in a first-line setting. The median follow-up was 35 months (IQR 29–52). Two patients (8.7%) experienced intravesical recurrence (both carcinoma in situ). Median RFS was 35 months (IQR 26–50), with 1- and 2-year RFS rates of 100.0% and 95.6%, respectively. No patient experienced progression, extravesical recurrence, cancer-specific death, or required radical cystectomy. Conclusion: First-line epirubicin-based HIVEC in BCG-naive patients provided durable oncological control in predominantly high- and very high-risk NMIBC. These results indicate that epirubicin-based HIVEC may represent a potential alternative when BCG is unavailable or contraindicated. However, the small sample size and observational design limit interpretability, underscoring the need for larger randomized trials to clarify the role of epirubicin-based HIVEC in this setting.
- Open Access
- 10 April 2026
- Published by Elsevier in Prostate International
- Vol. 14 (2) , 198-203
Omitting biopsy in Prostate Imaging Reporting and Data System 3? The role of Stockholm3 and prostate-specific antigen density findings from a prospective Swiss non-referral cohort
- 10 April 2026
- Published by Elsevier in Prostate International
- Vol. 14 (2) , 198-203
Open AccessOmitting biopsy in Prostate Imaging Reporting and Data System 3? The role of Stockholm3 and prostate-specific antigen density findings from a prospective Swiss non-referral cohort
- Open Access
- 23 February 2026
- Published by Elsevier in European Urology Open Science
- Vol. 86, 47-55
Oncological Outcomes of Epirubicin-based Hyperthermic Intravesical Chemotherapy in Bacillus Calmette-Guérin (BCG)-naïve Patients and Patients with BCG Failure: A Multicenter Retrospective Observational Study
- 23 February 2026
- Published by Elsevier in European Urology Open Science
- Vol. 86, 47-55
Open AccessOncological Outcomes of Epirubicin-based Hyperthermic Intravesical Chemotherapy in Bacillus Calmette-Guérin (BCG)-naïve Patients and Patients with BCG Failure: A Multicenter Retrospective Observational Study
- Open Access
- 16 January 2026
- Published by SAGE Publications in Bladder Cancer
- Vol. 12 (1)
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer
Introduction: Radical cystectomy or trimodal therapy are treatment options for non-metastatic bladder cancer. However, there is limited evidence guiding post-treatment follow-up regimens, resulting in variations in care. Objective: A Swiss consensus meeting aimed to identify gaps in follow-up strategies and subsequently tailoring follow-up protocols after curative treatment for bladder cancer. Methods: A consensus meeting including participants from urology, oncology, radiation oncology, neuro-urology, international advisors, and patient representatives was held. 19 pre-formulated questions addressing follow-up duration, frequency, and modalities after radical cystectomy or trimodal therapy for bladder cancer were discussed and voted by participants. Results: 42 experts from 22 institutions participated in the meeting. Agreement was reached on several important elements of oncological and functional follow-up like risk-adapted follow-up and regular usage of patient reported outcome measures (PROMs) and 3 novel personalized follow-up schedules were suggested, balancing oncological surveillance, and monitoring functional complications. Conclusion: We agreed on 3 newly developed Swiss follow up schedules for patients with bladder cancer who underwent cystectomy or trimodal therapy with curative intent; these protocols include stage-specific recommendations for type and timing of investigations to detect relapse combined with balanced measures to monitor functional complications such as PROMS and specific clinical examinations. These protocols will be evaluated in a prospective national multicentric cohort study.
- 16 January 2026
- Published by SAGE Publications in Bladder Cancer
- Vol. 12 (1)
Open AccessInterdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer
Introduction: Radical cystectomy or trimodal therapy are treatment options for non-metastatic bladder cancer. However, there is limited evidence guiding post-treatment follow-up regimens, resulting in variations in care. Objective: A Swiss consensus meeting aimed to identify gaps in follow-up strategies and subsequently tailoring follow-up protocols after curative treatment for bladder cancer. Methods: A consensus meeting including participants from urology, oncology, radiation oncology, neuro-urology, international advisors, and patient representatives was held. 19 pre-formulated questions addressing follow-up duration, frequency, and modalities after radical cystectomy or trimodal therapy for bladder cancer were discussed and voted by participants. Results: 42 experts from 22 institutions participated in the meeting. Agreement was reached on several important elements of oncological and functional follow-up like risk-adapted follow-up and regular usage of patient reported outcome measures (PROMs) and 3 novel personalized follow-up schedules were suggested, balancing oncological surveillance, and monitoring functional complications. Conclusion: We agreed on 3 newly developed Swiss follow up schedules for patients with bladder cancer who underwent cystectomy or trimodal therapy with curative intent; these protocols include stage-specific recommendations for type and timing of investigations to detect relapse combined with balanced measures to monitor functional complications such as PROMS and specific clinical examinations. These protocols will be evaluated in a prospective national multicentric cohort study.
- Open Access
Hyperthermic Intravesical Chemotherapy (HIVEC) Using Epirubicin in an Optimized Setting in Patients with NMIBC Recurrence after Failed BCG Therapy
To evaluate hyperthermic intravesical chemotherapy (HIVEC) using conductive heating and epirubicin in an optimized setting as an alternative to radical cystectomy in patients with recurrent non-muscle invasive bladder cancer (NMIBC) who have failed bacillus Calmette-Guérin (BCG) therapy. We retrospectively analyzed our prospectively recorded database of patients who underwent HIVEC between 11/2017 and 11/2022 at two Swiss University Centers. Cox regression analysis was used for univariate/multivariate analysis, and the Kaplan–Meier method for survival analysis. Of the 39 patients with NMIBC recurrence after failed BCG therapy, 25 (64%) did not recur within the bladder after a median follow-up of 28 months. The 12- and 24-month intravesical RFS were 94.8% and 80%, respectively. Extravesical recurrence developed in 14/39 (36%) of patients. Only 7/39 (18%) patients had to undergo radical cystectomy. Seven patients (18%) progressed to metastatic disease, with five of these (71%) having previously developed extravesical disease. No adverse events > grade 2 occurred during HIVEC. Device-assisted HIVEC using epirubicin in an optimized setting achieved excellent RFS rates in this recurrent NMIBC population at highest risk for recurrence after previously failed intravesical BCG therapy. Extravesical disease during or after HIVEC, however, was frequent and associated with metastatic disease and consecutively poor outcomes.
Open AccessHyperthermic Intravesical Chemotherapy (HIVEC) Using Epirubicin in an Optimized Setting in Patients with NMIBC Recurrence after Failed BCG Therapy
To evaluate hyperthermic intravesical chemotherapy (HIVEC) using conductive heating and epirubicin in an optimized setting as an alternative to radical cystectomy in patients with recurrent non-muscle invasive bladder cancer (NMIBC) who have failed bacillus Calmette-Guérin (BCG) therapy. We retrospectively analyzed our prospectively recorded database of patients who underwent HIVEC between 11/2017 and 11/2022 at two Swiss University Centers. Cox regression analysis was used for univariate/multivariate analysis, and the Kaplan–Meier method for survival analysis. Of the 39 patients with NMIBC recurrence after failed BCG therapy, 25 (64%) did not recur within the bladder after a median follow-up of 28 months. The 12- and 24-month intravesical RFS were 94.8% and 80%, respectively. Extravesical recurrence developed in 14/39 (36%) of patients. Only 7/39 (18%) patients had to undergo radical cystectomy. Seven patients (18%) progressed to metastatic disease, with five of these (71%) having previously developed extravesical disease. No adverse events > grade 2 occurred during HIVEC. Device-assisted HIVEC using epirubicin in an optimized setting achieved excellent RFS rates in this recurrent NMIBC population at highest risk for recurrence after previously failed intravesical BCG therapy. Extravesical disease during or after HIVEC, however, was frequent and associated with metastatic disease and consecutively poor outcomes.